Australia’s BlueMount Capital expands support of cross-border financings, M&A and leveraged buyouts with addition of industry veterans in Europe and North America
Melbourne (March 29, 2019) — BlueMount Capital today announced its expansion into Europe and North America with the appointments of Darren Shipard as Regional European Director based in London and Amiel Kornel as Senior Advisor, Venture Capital and Private Equity based in San Francisco and Paris.
Founded in 2010, BlueMount Capital (www.bluemountcapital.com) has grown into a global, mid-tier corporate finance and advisory group headquartered in Australia.
The firm, which has won a number of prestigious awards as corporate advisers, opened its Shanghai office in March 2017 and is scheduled to open a Beijing office in June 2019. BlueMount’s founding membership of the International Association of Investment Bankers also gives it a strong global reach through its partner members (www.iaib.org).
“Our presence on the ground in London, Paris and San Francisco will expand our client base and enhance our ability to assist clients with cross-border financings, mergers & acquisitions, and other transactional services,” said Managing Director Michael Shaw.
“Additionally, Darren and Amiel bring decades of successful operational and strategic advisory experience that will maximize value-accreting outcomes for clients.”
Darren Shipard has held senior management positions leading growth projects for large corporations in the automation and FMCG sectors and early-stage ventures in the oil and gas, cleantech and healthcare sectors across Australia, US and Europe. He most recently held the position of Partner for a management consultancy leading a global change management project covering 16 countries in both mature and emerging markets. He brings to BlueMount Capital extensive operational experience guiding the effective implementation of capital management, growth investment, change management and digital transformation projects.
Amiel Kornel, an experienced venture capitalist, board director and entrepreneur, has co- founded, financed and/or advised dozens of early and growth-stage ventures in the US and Europe. Industry sectors have included digital publishing, enterprise search, social media, and online marketplaces among others. He served as San Francisco-based senior managing director at a US venture capital firm for more than a decade. Amiel recently authored Spinning Into Control: Improvising the sustainable startup (Palgrave Macmillan, 2018), a book on new venture creation. A dual US-UK national, he speaks fluent English and French.
“We are delighted to welcome Darren and Amiel to the BlueMount team. They bring additional breadth and depth to our capabilities and services and complement our cross- border transaction capabilities and access to offshore sources of capital, M&A and collaborations,” said Dr. Saliba Sassine, Chairman of BlueMount Capital.
About BlueMount Capital
BlueMount Capital Group is an ASIC licensed, mid-tier, global investment banking and corporate advisory group headquartered in Australia. BlueMount’s team members are highly skilled professionals with global experience and a proven track record in equity and debt financings, M&A, Divestments, MBOs and MBIs, IPOs and RTOs and Cross Border transactions. BlueMount’s key areas of differentiation are its international market connectivity and the ability to perform a broad range of corporate advisory services. Its on- the ground representation in China, North America and Europe give clients the reach of major corporate finance houses with the service, feel and costs of a mid-tier group.
For more details contact: Dr Saliba Sassine
+61 412 533 966 Michael Shaw
+61 466 999 115
BlueMount Capital is pleased to report we are assisting an exciting Melbourne based antibody drug development Company to raise funds and with strategic advice.
Imunexus Ltd is a public unlisted Australian company that develops bispecific antibody based drugs.
The Company promises exceptional growth potential in the disciplines of clinical oncology and immunology. Innovative cancer therapeutics are driving value in the pharmaceutical industry, with many newly marketed engineered antibodies taking the lead in their fields.
Using its proprietary library of over 1010 (ten billion) engineered antibodies; Imunexus has identified several drug candidates that the Company aims to take through the drug development process.
Imunexus’ competitive advantage is that unlike most antibody therapeutic companies, Imunexus’ technology can be taken from concept to the identification of drug candidates within less than six months. This advantage is key to Imunexus’ potential.
Progressing, the Company has identified several drug candidates that possess drug-like characteristics. Of these, IMX101 is the closest to entering human clinical trials.
Targeting cancer, IMX101 was characterised and the Company appointed BlueMount to source the funds to complete formal Preclinical Studies that would enable IMX101 to enter Phase I human clinical trials. In parallel, Imunexus shall also advance its other drug candidates and identify new candidates.
With such a deep pool of investigational drugs, Imunexus is positioned to extract value via both 1) the development of drugs in human clinical trials and 2) license the development of non-core drug candidates to industry parties. BlueMount’s assignment comprises being the corporate advisor and are raising funds now of up to $5 million.
BlueMount Capital has been appointed as Corporate Advisor to PROJECT ENERGISE. The client carbonTRACK has developed advanced and innovative software and hardware which allows users to monitor, manage and optimize their energy usage, maximising savings and even allowing users to trade and arbitrage energy.
With its head office located in Melbourne, carbonTRACK commenced operations in 2015. Since then this award winning technology has been deployed in Australia New Zealand and Africa. Funds are now being raised to expand current operations and to support entry and growth in the U.S.A.
BlueMount Capital will lead the raising of $10m. An Investment Deck and Information Memorandum are now available and further details can be accessed on this website.